These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 28741720)

  • 21. Successful intravenous Alteplase for a centenarian woman with acute ischaemic stroke.
    He C; Sun Y; Yan B; Chen H; Zheng Y; Tang Y
    Clin Exp Pharmacol Physiol; 2019 May; 46(5):423-426. PubMed ID: 30697794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protamine reversal of low molecular weight heparin: clinically effective?
    van Veen JJ; Maclean RM; Hampton KK; Laidlaw S; Kitchen S; Toth P; Makris M
    Blood Coagul Fibrinolysis; 2011 Oct; 22(7):565-70. PubMed ID: 21959588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thromboelastographic changes in patients experiencing an acute ischemic stroke and receiving alteplase.
    Rowe AS; Greene CL; Snider CC; Carroll RC; Wiseman BF; Henry JM; Langdon JR; Craft RM
    J Stroke Cerebrovasc Dis; 2014 Jul; 23(6):1307-11. PubMed ID: 24439128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter Study of Intravenous Recombinant Tissue Plasminogen Activator Infusion around Hiroshima, Japan: The Hiroshima Acute Stroke Retrospective and Prospective Registry Study.
    Aoki S; Hosomi N; Sueda Y; Kono T; Takamatsu K; Ohyama H; Torii T; Kitamura T; Nomura E; Noda K; Ohtsuki T; Matsumoto M;
    J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2747-53. PubMed ID: 26360972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin.
    Prescrire Int; 2005 Aug; 14(78):146-52. PubMed ID: 16106599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel protamine variant reversal of heparin anticoagulation in human blood in vitro.
    Hulin MS; Wakefield TW; Andrews PC; Wrobleski SK; Stoneham MD; Doyle AR; Zelenock GB; Jacobs LA; Shanley CJ; TenCate VM; Stanley JC
    J Vasc Surg; 1997 Dec; 26(6):1043-8. PubMed ID: 9423721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Efficacy of Protamine Administration for Prevention of Bleeding Complications in Patients Undergoing TAVR.
    Al-Kassou B; Kandt J; Lohde L; Shamekhi J; Sedaghat A; Tabata N; Weber M; Sugiura A; Fimmers R; Werner N; Grube E; Treede H; Nickenig G; Sinning JM
    JACC Cardiovasc Interv; 2020 Jun; 13(12):1471-1480. PubMed ID: 32553337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.
    Parsons M; Spratt N; Bivard A; Campbell B; Chung K; Miteff F; O'Brien B; Bladin C; McElduff P; Allen C; Bateman G; Donnan G; Davis S; Levi C
    N Engl J Med; 2012 Mar; 366(12):1099-107. PubMed ID: 22435369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do anticoagulation with heparin and protamine reversal alter thrombogenicity of coated and noncoated pulmonary artery catheters?
    Youngberg JA; Kaye AD; Anwar M
    J Cardiothorac Vasc Anesth; 1999 Aug; 13(4):405-9. PubMed ID: 10468252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does Routine Reversal of Heparin With Protamine Sulphate in Patients Undergoing Carotid Endarterectomy Reduce Bleeding Complications Without Leading to Increased Thromboembolic Complications?
    Lynch NP; Kavanagh EG
    Eur J Vasc Endovasc Surg; 2016 Jan; 51(1):150. PubMed ID: 26482510
    [No Abstract]   [Full Text] [Related]  

  • 31. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SYNTHESIS expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast-track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke.
    Ciccone A; Valvassori L; Nichelatti M;
    Int J Stroke; 2011 Jun; 6(3):259-65. PubMed ID: 21557814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylactic administration of histamine 1 and/or histamine 2 receptor blockers in the prevention of heparin- and protamine-related haemodynamic effects.
    Kanbak M; Kahraman S; Celebioglu B; Akpolat N; Ercan S; Erdem K
    Anaesth Intensive Care; 1996 Oct; 24(5):559-63. PubMed ID: 8909666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy outcomes of protamine administration for heparin reversal following cryoballoon-based pulmonary vein isolation.
    Gurses KM; Kocyigit D; Yalcin MU; Evranos B; Yorgun H; Sahiner ML; Kaya EB; Oto MA; Ozer N; Aytemir K
    J Interv Card Electrophysiol; 2015 Aug; 43(2):161-7. PubMed ID: 25724721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator.
    Bissig D; Manjunath R; Traylor BR; Richman DP; Ng KL
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):e102-e104. PubMed ID: 28416406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Left ventricular apical thrombus after systemic thrombolysis with recombinant tissue plasminogen activator in a patient with acute ischemic stroke.
    Doepp F; Sanad W; Schreiber SJ; Baumann G; Borges AC
    Cardiovasc Ultrasound; 2005 May; 3():14. PubMed ID: 15918893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke.
    von Kummer R; Hacke W
    Stroke; 1992 May; 23(5):646-52. PubMed ID: 1579960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous thrombolysis in acute ischemic stroke after antagonization of unfractionated heparin with protamine: case series and systematic review of literature.
    Kneer K; Adeyemi AK; Sartor-Pfeiffer J; Wilke V; Blum C; Ziemann U; Poli S; Mengel A; Feil K
    Ther Adv Neurol Disord; 2023; 16():17562864221149249. PubMed ID: 36710724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is intra-arterial thrombolysis safe after full-dose intravenous recombinant tissue plasminogen activator for acute ischemic stroke?
    Shaltoni HM; Albright KC; Gonzales NR; Weir RU; Khaja AM; Sugg RM; Campbell MS; Cacayorin ED; Grotta JC; Noser EA
    Stroke; 2007 Jan; 38(1):80-4. PubMed ID: 17122433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of alteplase beyond 3 hours of ischemic stroke onset.
    Powers CM
    Adv Emerg Nurs J; 2011; 33(1):65-70. PubMed ID: 21317699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.